Panel: M&A in 2026: The Year Pharma Deals Change the Game

Session details:

• Why 2026 marks a turning point for pharma M&A and the forces accelerating deal activity  
• What’s driving momentum across capital markets, emerging modalities, and returning strategic assets  
• Where deal activity is likely to concentrate across therapeutic areas, technologies, and company stages  
• How valuation and risk frameworks are shifting and what buyers and investors are prioritizing  
• What will separate winners from laggards in a more competitive, time-sensitive deal environment